ArticleVeterinary research2025
Th17 cells/IL-17A shape Pasteurella multocida serotype A infection in murine and rabbit models.
Article in Veterinary research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Advances of Caspase-11 for veterinary respiratory infections.Frontiers in veterinary science · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Pasteurella multocida (Pm) is an important zoonotic respiratory pathogen, especially serotype A, which can cause death in various hosts, including humans, farm animals, and wildlife. However, the exact mechanisms by which hosts mobilize the immune system against Pasteurella multocida serotype A (PmA) in mammals remain largely unexplored. In the present study, we found that the control of lung infection is critical for PmA infection. Furthermore, unbiased RNA sequencing analysis and histopathological studies revealed that T-cell associated immunity was not fully activated during PmA infection, although the host tended to stimulate Th17 cell and interleukin (IL)-17A-related pathways. To investigate the role of Th17 cells/IL-17A, we employed gain- and loss-of-function Th17 cells and IL-17A at the animal level via inhibitors, through in vitro induction of Th17 cells followed by reperfusion and recombinant IL-17A, respectively. We demonstrated that the host failed to fully activate Th17 cells/IL-17A, which is a key immune mechanism against P. multocida infection. Mechanistic studies revealed that the IL-6-JAK2-STAT3 axis contributed to Th17 cell/IL-17A activation in PmA infection. Therefore, using the Stat3 inhibitor Stattic or IL-6KO mouse models significantly limited Th17 cell/IL-17A activation and accelerated host death. Importantly, recombinant IL-17A had strong potential for clinical application, as recombinant IL-17A effectively protected rabbits infected with PmA. Thus, our study revealed that PmA induced T-cell immunodeficiency, and that the activation of Th17 cells/IL-17A via the IL-6-JAK2-STAT3 axis was a key mechanism against PmA. Therefore, targeting Th17 cells/IL-17A could be a potential strategy for the treatment of pasteurellosis and other respiratory bacterial diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.